[1] J. Reedijk, “Comprehensive Coordination Chemistry, Vol. 2,” In: G. Wilkinson, R. D. Dillard and J. A. McCleverty, Eds., Comprehensive Coordination Chemistry, Pergamon, Oxford, 1987, p. 73.
[2] S. Kumar, D. N. Dhar and P. N. Saxena, “Applications of Metal Complexes of Schiff Bases—A Review,” Journal of Scientific and Industrial Research, Vol. 68, No. 3, 2009, pp. 181-187.
[3] Y. Shen and B. P. Sullivan, “Versatile Preparative Route to 5-Substituted-1,10-phenanthroline Ligands via 1,10-Phenanthroline-5,6-epoxide,” Inorganic Chemistry, Vol. 34, No. 25, 1995, pp. 6235-6236.
http://dx.doi.org/10.1021/ic00129a003
[4] Md. A. Masood and P. S. Zacharias, “Electrochemical Reversibility of the CuI-Cu0 Couple in Bis[2,9-di(o-substituted phenyl)-1,10-phenanthroline]-copper(I) Complexes. Stability of the Corresponding Copper(0) Species,” Journal of the Chemical Society, Dalton Transactions, No. 1, 1991, pp. 111-114.
http://dx.doi.org/10.1039/dt9910000111
[5] A. Zaid, J.-S. Sun, C.-H. Nguyen, E. Bisagni, T. Garestier, D. S. Grierson and R. Zain, “Triple-Helix Directed Cleavage of Double-Stranded DNA by Benzoquinoquinoxaline-1,10-phenanthroline Conjugates,” ChemBioChem, Vol. 5, No. 11, 2004, pp. 1550-1557.
http://dx.doi.org/10.1002/cbic.200400074
[6] H. Amiri, N. Nekhotiaeva, J.-S. Sun, C.-H. Nguyen, D. S. Grierson, L. Good and R. Zain, “Benzoquinoquinoxaline Derivatives Stabilize and Cleave H-DNA and Repress Transcription Downstream of a Triplex-forming Sequence,” Journal of Molecular Biology, Vol. 35, No. 4, 2005, pp. 776-783.
http://dx.doi.org/10.1016/j.jmb.2005.03.044
[7] T. K. Goswami, S. Gadadhar, A. A. Karande and A. R. Chakravarty, “Photocytotoxic Ferrocene-Appended (l-Tyrosine)copper(II) Complexes of Phenanthroline Bases,” Polyhedron, Vol. 52, 2013, pp. 1287-1298.
http://dx.doi.org/10.1016/j.poly.2012.06.018
[8] M. A. Masood and D. J. Hodgson, “Synthesis and Characterization of the Multidentate Ligand 2,9-Bis(N-pyrazolylmethyl)-1,10-phenanthroline (bpmp) and Its Copper(I) and Copper(II) Complexes,” Inorganic Chemistry, Vol. 32, No. 22, 1993, pp. 4839-4844.
http://dx.doi.org/10.1021/ic00074a031
[9] E. M. Bavin, R. J. W. Reea, J. M. Robson, M. Seiler, D. E. Seymour and D. Suddaby, “The Tuberculostatic Activity of Some Thiosemicarbazones,” Journal of Pharmacy and Pharmacology, Vol. 2, No. 1, 1950, pp. 764-772.
http://dx.doi.org/10.1111/j.2042-7158.1950.tb12999.x
[10] G. A. Kune, “To-Day’s Drug: Methisazone,” British Medical Journal, Vol. 2, 1964, p. 621.
[11] A. C. Sartorelli and B. A. Booth, “Inhibition of the Growth of Sarcoma 180 Ascites Cells by Combinations of Inhibitors of Nucleic Acid Biosynthesis and the Cupric Chelate of Kethoxal Bis-(thiosemicarbazone),” Cancer Research, Vol. 27, No. 9, 1967, pp. 1614-1619.
[12] C. M. Nutting, C. M. L. Herpan and A. B. Miah, “Phase II Study of 3-AP Triapine in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,” Annals of Oncology, Vol. 20, No. 7, 2009, pp. 1275-1279.
http://dx.doi.org/10.1093/annonc/mdn775
[13] S. H. N. Moorthy, M. F. S. A. Cerqueira, J. Ramos and A. Farnandes, “Aryl- and Heteroaryl-Thiosemicarbazone Derivatives and Their Metal Complexes: A Pharmacological Template,” Anticancer Drug Discovery, Vol. 8, No. 2, 2013, pp. 148-152
[14] B. Ma, B. C. Goh and E. H. Tan, “A Multicenter Phase II trial of 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone (3-AP, Triapine®) and Gemcitabine in Advanced Non-Small-Cell Lung Cancer with Pharmacokinetic Evaluation Using Peripheral Blood Mononuclear Cells,” Investigational New Drugs, Vol. 26, No. 2, 2008, pp. 169-173. http://dx.doi.org/10.1007/s10637-007-9085-0
[15] Md. Arifuzzaman, M. R. Karim, T. A. Siddiquee, A. H. Mirza and M. A. Ali, “Synthesis and Characterization of New Schiff Bases Formed by Condensation of 2,9-Phenathroline-1,10-dialdehyde with Sulfur-Containing Amines,” International Journal of Organic Chemistry, Vol. 3, No. 1, 2013, pp. 81-86.
[16] G. M. Sheldrick, “Program for the Solution and Refinement of Crystal Structures,” University of Gottingen, Gottingen, 1997.
[17] CrystalClear: Rigaku Corporation, “CrystalClear Software User’s Guide, Molecular Structure Corporation,” Rigaku Corporation, 1999, pp. 1718-1725.
[18] Crystal Crystallography, “WinGX Suite for Small-Molecule Single-Crystal Crystallography,” Journal of Applied Crystallography, Vol. 32, 1999, pp. 837-838.
http://dx.doi.org/10.1107/S0021889899006020
[19] S. K. Sahoo, N. Khatun, A. Gogoi, A. Deb and B. K. Patel, “Cu(II) Catalysed Chemoselective Oxidative Transformation of Thiourea to Thioamidoguanidine/2-aminobenzothiazole,” RSC Advances, Vol. 3, No. 2, 2013, pp. 438-446.
[20] A. Thapper, A. C. Rizzi, C. D. Brondino, A. G. Wedd, R. J. Pais, B. K. Maiti, I. Moura and S. R. Pauelta, “Copper-Substituted Forms of the Wild Type and C42A Variant of Rubredoxin,” Journal of Inorganic Biochemistry, Vol. 127, 2013, pp. 232-237.